Updates on HER2-Directed ADCs Across Solid Tumors - Episode 13

Managing Hematologic AEs Associated with ADC Treatments

, , , ,

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Assessing HER2 Status Across Tumor Types
    EP. 2: ADCs Targeting HER2+ Breast Cancer
    EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
    EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
    EP. 5: ADCs Targeting GI Cancers
    EP. 6: ADCs Targeting HER2+ Lung Cancer
    EP. 7: Impact of ADCs on Brain Metastases
    EP. 8: ADCs Targeting HER2+ GU Cancers
    EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
    EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
    EP. 11: Managing ILD and Pneumonitis Risk From ADCs
    EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
    Now Viewing
    EP. 13: Managing Hematologic AEs Associated with ADC Treatments
    EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
    EP. 15: ADC Sequencing
    EP. 16: Emerging ADCs in Development
    EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
    EP. 18: The Future for HER2-Directed ADCs
    EP. 19: Key Takeaways and Closing Thoughts on ADCs
    x